Yosr Z. Haffani

Prof. Dr. Yosr Z. Haffani

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Molecular Cell
Verified
Journal Article
Closed access
DMDaniel Y.L. Mao
Daniel Y.L. Mao
DNDante Neculai
Dante Neculai
MDMichael Downey
Michael Downey
SOStephen Orlicky
Stephen Orlicky
YHYosr Z. Haffani
Yosr Z. Haffani
FSFrank Sicheri
Frank Sicheri

13 April 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CRCarla O. Rosario
Carla O. Rosario
MKMichael A. Ko
Michael A. Ko
YHYosr Z. Haffani
Yosr Z. Haffani
Rebecca GladdyRebecca Gladdy
Rebecca Gladdy
JPJana Paderova
Jana Paderova
CSCarol J. Swallow
Carol J. Swallow
Aneuploidy is a characteristic feature of established cancers and can promote tumor development. Aneuploidy may arise directly, through unequal distribution of chromosomes into daughter cells, or indirectly, through a tetraploid intermediate. The polo family kinase Plk4/Sak is required for late mitotic progression and is haploinsufficient for tumor suppression in mice. Here we show that loss of heterozygosity (LOH) occurs at the Plk4 locus in 50% of human hepatocellular carcinomas (HCC) and is present even in preneoplastic cirrhotic liver nodules. LOH at Plk4 is associated with reduced Plk4 expression in HCC tumors but not with mutations in the remaining allele. Plk4 +/− murine embryonic fibroblasts (MEFs) at early passage show a high incidence of multinucleation, supernumerary centrosomes, and a near-tetraploid karyotype. Underlying these phenotypes is a high rate of primary cytokinesis failure, associated with aberrant actomyosin ring formation, reduced RhoA activation, and failure to localize the RhoA guanine nucleotide exchange factor Ect2 to the spindle midbody. We further show that Plk4 normally localizes to the midbody and binds to and phosphorylates Ect2 in vitro. With serial passaging Plk4 +/− MEFs rapidly immortalize, acquiring an increasing burden of nonclonal and clonal gross chromosomal irregularities, and form tumors in vivo. Our results indicate that haploid levels of Plk4 disrupt RhoGTPase function during cytokinesis, resulting in aneuploidy and tumorigenesis, thus implicating early LOH at Plk4 as one of the drivers of human hepatocellular carcinogenesis. These findings represent an advance in our understanding of genetic predisposition to HCC, which continues to increase in incidence globally and particularly in North America.

1 July 2004 in Plant Molecular Biology
Verified
Journal Article
Closed access
PDF file
YHYosr Z. Haffani
Yosr Z. Haffani
TGThierry Gaude
Thierry Gaude
JCJ. Mark Cock
J. Mark Cock
DGDaphne Goring
Daphne Goring

4 June 2019 in AAS Open Research
Verified
Journal Article
Open access
PDF file
Collet DandaraCollet Dandara
Collet Dandara
CMCollen Masimirembwa
Collen Masimirembwa
YHYosr Z. Haffani
Yosr Z. Haffani
BOBernhards Ogutu
Bernhards Ogutu
JMJenniffer Mabuka
Jenniffer Mabuka
HAH3 Africa
H3 Africa
The African Pharmacogenomics Consortium (APC) was formally launched on the 6th September 2018. This white paper outlines its vision, and objectives towards addressing challenges of conducting and applying pharmacogenomics in Africa and identifies opportunities for advancement of individualized drugs use on the continent. Africa, especially south of the Sahara, is beset with a huge burden of infectious diseases with much co-morbidity whose multiplicity and intersection are major challenges in achieving the sustainable development goals (SDG), SDG3, on health and wellness. The profile of drugs commonly used in African populations lead to a different spectrum of adverse drug reactions (ADRs) when compared to other parts of the world. Coupled with the genetic diversity among Africans, the APC is established to promote pharmacogenomics research and its clinical implementation for safe and effective use of medicine in the continent. Variation in the way patients respond to treatment is mainly due to differences in activity of enzymes and transporters involved in pathways associated with each drug’s disposition. Knowledge of pharmacogenomics, therefore, helps in identifying genetic variants in these proteins and their functional effects. Africa needs to consolidate its pharmacogenomics expertise and technological platforms to bring pharmacogenomics to use.

1 January 2004 in Canadian Journal of Botany
Verified
Journal Article
Closed access
YHYosr Z. Haffani
Yosr Z. Haffani
NSNancy F Silva
Nancy F Silva
DGDaphne Goring
Daphne Goring
Recent plant genome analyses have revealed a large family of plant receptor kinases with very divergent extracellular domains. While a large proportion of this family remains uncharacterized, emerging functions for several plant receptor kinases reveal roles in a variety of biological processes including growth, development, hormone perception, and plant–microbe interactions. Significant progress has also been made in the understanding of four plant receptor kinase systems including their respective ligands and signalling pathways. Interestingly, a wide range of signalling proteins have been identified as functioning with these receptor kinases. In this review, an overview of plant receptor kinases, their biological functions, and their signalling pathways is presented.Key words: plants, Arabidopsis, receptor kinase, signal transduction.

1 September 2006 in Plant Signaling & Behavior
Verified
Journal Article
Closed access
YHYosr Z. Haffani
Yosr Z. Haffani
NSNancy Silva-Gagliardi
Nancy Silva-Gagliardi
SSSarah Sewter
Sarah Sewter
MAMay Grace Aldea
May Grace Aldea
ZZZhiying Zhao
Zhiying Zhao
DGDaphne Goring
Daphne Goring
The proline-rich, extensin-like receptor kinase (PERK) family is characterized by a putative extracellular domain related to cell wall proteins, followed by a transmembrane domain and kinase domain...